Histone methyltransferase G9a has critical roles in promoting cancercell growth and gene suppression, but whether it is also associated with the DNA damage response is rarely studied. Here, we report that loss of G9a impairs DNA damage repair and enhances the sensitivity of cancer cells to radiation and chemotherapeutics. In response to DNA double-strand breaks (DSBs), G9a is phosphorylated at serine 211 by casein kinase 2 (CK2) and recruited to chromatin. The chromatin-enriched G9a can then directly interact with replication protein A (RPA) and promote loading of the RPA and Rad51 recombinase to DSBs. This mechanism facilitates homologous recombination (HR) and cell survival. We confirmed the interaction between RPA and G9a to be critical for RPA foci formation and HR upon DNA damage. Collectively, our findings demonstrate a regulatory pathway based on CK2-G9a-RPA that permits HR in cancer cells and provide further rationale for the use of G9a inhibitors as a cancer therapeutic.
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double-strand break | G9a | RPA | CK2 | homologous recombination T he human genome is constantly challenged by spontaneous DNA metabolism and environmental agents that can induce DNA lesions (1, 2) . To maintain genomic integrity, cells have evolved a complex protective mechanism known as the DNA damage response (DDR) to sense signals of DNA damage and repair different types of DNA lesion (3) . Of all of the distinctive types of DNA lesion, DNA double-strand breaks (DSBs) are the most cytotoxic, and defects in repairing such lesion can result in genomic instability and lead to cancer (1, 4) . There are two major pathways to repair DSBs-homologous recombination (HR) and nonhomologous end joining (NHEJ). HR is an error-free process that can occur only during the S and G2/M phases of the cell cycle. Conversely, NHEJ is an error-prone process that can operate throughout the cell cycle (5, 6) . A key step in determining whether HR or NHEJ may occur is DNA end resection-a process that produces 3′ single-stranded DNA (ssDNA) tails (7) . These newly created tails bind to Rad51 recombinase, which initiates DNA pairing and strand invasion (8) . Replication protein A (RPA) is a heterotrimeric protein complex composed of RPA70, RPA32, and RPA14 that also binds to the 3′ ssDNA tails. Upon binding, RPA activates an ATR-Chk1-dependent G2/M DNA damage checkpoint (9) (10) (11) . The Mre11-Rad50-Nbs1 (MRN) complex, CtIP (RBBP8), and BRCA1 have all been identified as major regulators that initiate DNA end resection (12) (13) (14) . Conversely, 53BP1 is thought to prevent DNA end resection and thus facilitates NHEJ (15) .
The dense packaging of nuclear DNA into chromatin is an obstacle to DNA repair (16, 17) , and many studies have emphasized the importance of chromatin regulators, such as histone methylations and their corresponding modifiers, in the DDR. The levels of histone H3K36 dimethylation (H3K36me2) increase following DSBs as a result of either the dissociation of the histone demethylase KDM2A from chromatin or the catalytic activity of the histone methyltransferase Metnase, and recruit either the MRN complex or Ku70 family proteins to DSBs, respectively (18, 19) . Suv39h1-mediated histone H3K9 trimethylation (H3K9me3) at DSBs directly binds to and activates Tip60-a histone acetylase that is essential for ataxia-telangiectasia-mutated (ATM) activation (20, 21) . In addition, PR-Set7 cooperates with Suv4-20 to promote histone H4K20 dimethylation (H4K20me2) to permit the binding of 53BP1 to DSBs (22, 23) . Thus, it is likely that any enzyme that alters local chromatin structure surrounding the damaged DNA sites will influence the capacity of the DDR.
G9a is the primary enzyme for histone H3K9 monomethylation (H3K9me1) and dimethylation (H3K9me2) in euchromatin (24, 25) . Global knockout of G9a in mice is embryonic lethal due to a severe growth limitation (26) . In addition, the expression levels of G9a are often up-regulated in various human cancers (27) . Depletion of G9a in cancer cells inhibits cell growth, leads to chromosome instability, and markedly reduces tumor growth (28) (29) (30) . Interestingly, signaling of DNA damage in senescent cells induces proteasome-dependent degradation of G9a (31) and application of a G9a inhibitor (UNC0638) in combination with a low dose of the DNA damage agents phleomycin and etoposide is shown to selectively attenuate cancer-cell proliferation (32) . These findings lead us to hypothesize that G9a may be involved in the DDR following DNA damage.
Significance
The G9a histone methyltransferase primarily regulates the expression of genes associated with cancer development in cancer cells, but it has also been implicated in mediating the DNA damage response. Here, we confirmed a role for G9a in DNA damage repair following double-strand breaks. G9a is recruited to chromatin as a result of casein kinase 2-mediated phosphorylation, where it directly interacts with replication protein A (RPA). G9a binding to RPA modulates RPA and Rad51 foci formation and permits efficient homologous recombination. This molecular mechanism renders cancer cells more resistant to radiation and chemotherapeutics. Our improved understanding of the molecular function of G9a may help with the future design of G9a inhibitors and G9a-based DNA damage agents as cancer therapeutics.
In this study, we identified that G9a can regulate HR in response to DSBs. G9a deficiency impairs DNA damage repair and sensitizes cancer cells to DSBs by disrupting RPA and Rad51 foci formation. This action of G9a is dependent on casein kinase 2 (CK2), which phosphorylates G9a at serine 211 to permit its recruitment to chromatin. In addition, we found that direct binding of G9a to RPA70 is indispensable for G9a function in DNA damage repair and that this effect was independent of its methyltransferase activity. Altogether, our data demonstrate that G9a is directly involved in HR following DNA damage in human cancer cells, which will be useful for the design of new cancer therapeutics, particularly for those patients with elevated G9a levels.
Results
G9a Is Required for DNA Damage Repair. We first investigated whether G9a is required for DNA damage repair in human colorectal carcinoma HCT116 cells by producing a G9a knockout cell line (here referred to as G9a-KO and the parental cells referred to as G9a-WT) using the CRISPR-Cas9 technique. Although knockout of G9a in mice is embryonic lethal (26), G9a-KO HCT116 cells, similar to G9a knockout embryonic stem cells (26) , are viable. The G9a knockout efficiency and specificity was confirmed by Western blotting and DNA sequencing ( Fig. S1 A and B). Consistent with previous reports (33, 34) , G9a knockout cells exhibited more spontaneous DNA damage and reduced DNA replication and colony formation capacity, thus strengthening the idea that G9a is required for cell proliferation (Fig. S1 C-E). We then used a comet assay to directly measure the efficiency of DNA repair in these cells after inducing DNA damage with irradiation (IR) or etoposide (VP16). As shown in Fig. 1 A and B, there was a negligible difference between the comet tails in G9a-KO and G9a-WT cells 1 h after DNA damage treatment; however, significant DNA damage, as indicated by increased comet-tail length and area (35) , was detected in the G9a-KO cells 6 h post IR or 18 h after VP16 withdrawal, compared with G9a-WT cells (P < 0.05).
H2AX is phosphorylated at Ser139 (γ-H2AX) in response to DNA damage, and the levels of γ-H2AX have been widely used as a sensitive marker for DSBs (36) . We therefore analyzed γ-H2AX foci formation in G9a-WT or G9a-KO cells by immunofluorescence. Microscopic analyses identified that γ-H2AX foci were formed in both the G9a-WT and G9a-KO cells 1 h post DNA damage, but at 6 h post IR or 18 h after VP16 withdrawal, the majority of γ-H2AX foci returned to basal levels in the G9a-WT cells, whereas the G9a-KO cells still exhibited visible γ-H2AX foci (P < 0.05), suggesting that lack of G9a impaired DNA damage repair ( Fig. 1 C and D) . We next performed Western blotting to further confirm the dynamic changes in γ-H2AX levels and obtained similar data to those described above (Fig. S1 F and G) . Finally, a colony formation assay was used to determine if G9a depletion sensitizes cancer cells to DSBs. As shown in Fig. 1E , the G9a-KO cells exhibited a much lower survival rate following DNA damage treatment compared with the G9a-WT cells (P < 0.05). Altogether, these data indicate that G9a is involved in DNA damage repair and thus affects cell survival.
G9a Is Recruited to Chromatin in Response to DNA Damage. Previous work has shown that G9a is degraded in response to DNA damage The data represent the means ± SD (n ≥ 100) from three independent experiments. (E) Colony formation assay for G9a-WT or G9a-KO cells. The survival fraction was calculated, and the data represent the means ± SD from three independent experiments. Student's t test (twotailed): G9a-KO versus G9a-WT, P < 0.05.
in primary human diploid fibroblasts (31) . Here, the total G9a protein levels did not change in HCT116, HeLa, or LoVo cancer cells following DNA damage (Fig. S2A) . Interestingly, we found that G9a moved from the soluble portion of the nucleoplasm to nuclear chromatin upon IR or exposure to the chemotherapeutics VP16 or camptothecin (CPT), suggesting that the movement of G9a to chromatin is a universal response to DSBs ( Fig. 2 A and  B) . In addition, its movement in response to VP16 treatment occurred in a dose-dependent and time-dependent manner ( Fig. 2 C  and D) . To examine the dynamic enrichment of G9a at sites of DNA damage, HCT116 and HeLa cells were transfected with fulllength G9a tagged with a GFP epitope (GFP-G9a) and then observed under a fluorescence microscope after irradiation with a 365-nm UV laser beam. As shown in Fig. 2 E and F, G9a accumulation at DNA damage stripes reached a plateau ∼180 s after laser microirradiation. In addition, the enzyme-dead GFP-G9a (Y1154F) protein, in which a tyrosine was changed to phenylalanine and the N terminus GFP-G9a (1-630 aa) protein alone was also recruited to DNA damage stripes, suggesting that the N terminus but not its methylation activity is essential for G9a recruitment ( Fig. S2B) . A cellular assay using the DR-GFP U2OS reporter system was also used to monitor the recruitment of G9a to DSBs. Briefly, DR-GFP U2OS cells are stably incorporated with two separate GFP genes, one of which contains a recognition site for endonuclease I-SceI. A DSB site can be generated by overexpression of I-SceI, and the recruitment of DNA-responsive proteins at DSBs can be detected by confocal microscopy or chromatin immunoprecipitation (ChIP) (37). Although we were unable to observe visible G9a foci at I-SceI-induced DSB sites, possibly because of the low sensitivity of our anti-G9a antibody, G9a did colocalize with γ-H2AX (Fig. S2D ). In addition, the ChIP assay indicated that, following overexpression of I-SceI, G9a was recruited to the DSB site (an approximately twofold increase), and the change in G9a cellular localization was similar to that of Rad51-a DNA damage responsive protein that was used as a positive control (Fig. 2G ). These data indicate that G9a is recruited to chromatin in response to DNA damage.
CK2 Catalyzes G9a Phosphorylation in Vivo and in Vitro. We next explored how G9a is recruited to chromatin in response to DSBs by analyzing the G9a posttranslational modifications that occur upon VP16 or CPT treatment. We found that Serine/Threonine (Ser/Thr) phosphorylation of G9a markedly increased after VP16 or CPT treatment, whereas other posttranslational modifications, including tyrosine (Tyr) phosphorylation and lysine (Lys) methylation, remained unchanged (Fig. 3A) . In addition, increases in Ser/Thr phosphorylation were abolished by λ-phosphatase (λ-PPase) treatment, thus supporting the idea that G9a is phosphorylated in response to DNA damage (Fig. 3B ). To determine whether the increased levels of Ser/Thr phosphorylation were required for G9a recruitment to chromatin, the G9a protein levels in various subcellular compartments were investigated after treatment with VP16, with or without multiple kinase inhibitors. The recruitment of G9a to chromatin was not affected by inhibitors targeting the PIKK family members ATM, ATR, or DNA-PK ( to chromatin upon VP16 treatment was attenuated by 4,5,6,7-tetrabromobenzotriazole (TBB)-an inhibitor that specifically targets CK2 (Fig. 3C and Fig. S3D ). In addition, HCT116 cells were transiently transfected with an siRNA against CK2 followed by VP16 treatment. As shown in Fig. 3D , siRNA-mediated CK2 knockdown also attenuated G9a enrichment on chromatin in response to VP16 treatment. Moreover, the CK2 inhibitor TBB, but not the ATM inhibitor KU55933, impaired the accumulation of GFP-G9a at the DNA damage stripes (Fig. 3E ). To investigate if G9a is phosphorylated by CK2 in vivo, the Ser/Thr phosphorylation levels of G9a were studied in HCT116 cells in which FLAG-tagged WT CK2 [FLAG-CK2 (WT)] or FLAG-tagged CK2 mutant [FLAG-CK2 (K68M)] with defective enzymatic activity was overexpressed. The Ser/Thr phosphorylation levels of exogenous G9a were increased in cells transfected with FLAG-CK2 (WT), but not in cells transfected with FLAG-CK2 (K68M) (Fig. 3F ). In addition, the Ser/Thr phosphorylation levels of G9a were no longer increased upon VP16 treatment in HCT116 cells transfected with CK2 siRNA (Fig. 3G) . Moreover, the in vitro kinase catalytic assay showed that G9a was effectively phosphorylated by FLAG-CK2 (WT) but not by FLAG-CK2 (K68M) (Fig. 3H) . We conclude therefore that CK2 is the enzyme responsible for G9a phosphorylation and its changes in subcellular localization in response to DNA damage.
Phosphorylation of G9a at Ser211 Permits Its Recruitment to Chromatin.
To identify the specific CK2 phosphorylation sites on G9a, we incubated recombinant G9a with functional CK2 and then performed mass spectrometry (MS). These MS data indicated that Serine 211 (Ser211) was the site of CK2 phosphorylation (Fig.  S4A ). To confirm this result, a G9a Ser-211 to alanine 211 mutant [G9a (S211A)] was generated, and an in vitro phosphorylation assay was performed with either recombinant G9a (WT) or G9a (S211A) as substrates. As shown in Fig. 4A , G9a (WT) was phosphorylated by CK2, but the G9a S211A mutation markedly abrogated G9a phosphorylation. In addition, alignment of the sequence surrounding the Ser211 site in different species indicated that the surrounding sequence is conserved in mammals but not in Danio rerio or Drosophila melanogaster (Fig. S4B) . We then used (E) HeLa cells were transfected with GFP-G9a (WT), pretreated with TBB or KU55933 (10 μM, 6 h), and then irradiated with a 365-nm UV laser beam. Images were collected every 20 s after laser microirradiation. The arrows indicate the irradiation path. (F) HCT116 cells were cotransfected with either GFP-G9a plus FLAG-CK2 (WT) or GFP-G9a plus FLAG-CK2 (K68M) for 48 h. GFP-G9a immunoprecipitates were subjected to immunoblotting with the indicated antibodies. GFP-G9a was used as a loading control. (G) HCT116 cells were transfected with an siRNA against CK2 for 24 h followed by transfection with FLAG-G9a for 48 h. FLAG-G9a immunoprecipitates were subjected to immunoblotting with the indicated antibodies. (H) HCT116 cells were transfected with FLAG-CK2 (WT) or FLAG-CK2 (K68M), and the FLAG immunoprecipitates were incubated with bacterially purified G9a (WT) in vitro. Western blotting was performed with the indicated antibodies to detect G9a phosphorylation.
coimmunoprecipitation (Co-IP) to study whether Ser211 phosphorylation is required for G9a recruitment to chromatin upon DNA damage by monitoring the interaction between various G9a mutants (WT, S211A, and S211D) and histone H3. As shown in Fig. 4B , the interaction between G9a (S211A) and H3 was markedly decreased compared with both the G9a (WT) and G9a (S211D) mutant, in which a change from serine to aspartic acid mimics phosphorylation. In addition, cells expressing G9a (S211A) exhibited reduced G9a chromatin enrichment, whereas the enrichment of G9a (WT) and G9a (S211D) on chromatin was comparable (Fig. 4C) . Moreover, the translocation of G9a from the nucleoplasm to chromatin upon VP16 treatment was attenuated in the presence of the S211A mutation (Fig. 4D) . Furthermore, live-cell imaging revealed that the S211A mutation caused reduced recruitment of G9a to sites of DNA damage, whereas the G9a (S211D) mutation enhanced its accumulation at damaged DNA sites (Fig. 4 E and F) . Importantly, the methyltransferase activity of G9a remained unchanged between G9a (WT) and G9a (S211A) (Fig. S4C) . Taken together, these findings indicate that phosphorylation of G9a at Ser211 promotes its recruitment to chromatin by enhancing its chromatin-binding capacity but not by altering its methyltransferase activity.
G9a Interacts with RPA in Vivo and in Vitro. To investigate how chromatin-enriched G9a contributes to DNA damage repair, the possible G9a-interacting proteins were identified in HCT116 cells transfected with FLAG-G9a by MS. We identified several well-known G9a-interacting proteins, including CDYL, WIZ, and GLP (25, 38, 39) , as well as the novel binding partners RPA70 and RPA32 (Fig. S5A) . To confirm this result, a series of Co-IP assays were performed in HCT116 cells. Consistent with the MS results, endogenous RPA70 and RPA32 were precipitated by exogenous FLAG-G9a (Fig. S5B) , and the interaction between them markedly increased upon DNA damage (Fig. 5A) . In addition, endogenous G9a and the RPA complex were mutually precipitated by each other under physiological conditions (Fig. 5B and Fig. S5C) . Moreover, the endogenous interaction between G9a and RPA decreased in the soluble nucleoplasm fraction and increased in the chromatin-containing fraction upon VP16 treatment (Fig. 5C ). To confirm whether RPA70 or RPA32 interacted with G9a, we performed Co-IP assays in HCT116 cells by cotransfecting either GFP-G9a and FLAG-tagged RPA70 (FLAG-RPA70) or GFP-G9a and FLAG-tagged RPA32 (FLAG-RPA32). As shown in Fig. 5 D and E, GFP-G9a and FLAG-RPA70 were mutually precipitated; however, GFP-G9a failed to immunoprecipitate FLAG-RPA32, perhaps implying that G9a has a preferential interaction with RPA70 over RPA32 in vivo. Mutant G9a (S211A) also exhibited reduced binding affinity for RPA70 compared with G9a (WT) and G9a (S211D), suggesting that phosphorylation of G9a at Ser211 facilitates G9a binding to RPA70 (Fig. 5F ). To verify whether the interaction between G9a and the RPA complex is direct, a GST pull-down assay was performed. As shown in Fig. 5G and Fig. S5D , G9a directly interacted with RPA70 and RPA32. We then refined the GST pull-down assay to map the mutual interacting domains between G9a and RPA70. As shown in Fig. 5H , full-length G9a, G9a (1-350 aa), and G9a (350-630 aa) were pulled down by RPA70, but not G9a (630-960 aa) or G9a (960-1210 aa), suggesting that G9a interacts with RPA70 via the N terminus [G9a (1-630 aa) ]. The interactions between these different G9a fragments and RPA70 were then investigated in vivo. Concordant with the in vitro data, RPA70 exhibited a preferential interaction with G9a (1-630 aa) (Fig. 5I) . In addition, the RPA70 N terminus (1-211 aa) was confirmed to be required for G9a binding (Fig. S5E) . H3K9me2 interacts with the BARD/BRCA1 complex through HP1γ (40) , and therefore, it should be ruled out that the function of G9a in response to DNA damage may be mediated by H3K9me2. To assess this possibility, a peptide pull-down assay was performed to detect H3K9me2-interacting proteins. The assay indicated that RPA70, Rad51, BRCA1, and CtIP did not interact with the biotin-labeled H3K9me2 peptide, whereas G9a and HP1γ (41, 42) , two positive controls, were pulled down (Fig.  S5F) . These results suggest that G9a, but not H3K9me2, binds to RPA70 in response to DNA damage.
G9a Depletion Impairs Loading of the RPA and Rad51 to DSBs. Subsequently, the RPA and Rad51 foci formation in HCT116 G9a-WT or G9a-KO cells was tested to assess whether G9a can modulate RPA function upon DNA damage. As shown in Fig. 6 A and B, IR exposure or VP16 treatment resulted in a significantly higher number of RPA and Rad51 foci in G9a-WT cells compared with that in G9a-KO cells (P < 0.05). In addition, the cell-cycle distribution was unaltered, indicating that no specific cell-cycle stage is perturbed following G9a depletion (Fig. S6A) . The same experiments were repeated and confirmed in HeLa cells (Fig. S6B) . The recruitment of DNA-responsive proteins upstream of RPA, such as BRCA1, 53BP1, and MRE11, was not impaired by G9a deficiency (Fig. S6C) . Moreover, the recruitment of Cherry-tagged RPA70 to the IR path was significantly delayed in HCT116 G9a-KO cells (D) HCT116 cells were cotransfected with GFP-G9a and FLAG-RPA70 or GFP-G9a and FLAG-RPA32. The GFP immunoprecipitates were analyzed using anti-FLAG or anti-GFP antibodies. (E) HCT116 cells were cotransfected with GFP-G9a and FLAG-RPA70 (a), GFP-G9a and FLAG-RPA32 (b), or GFP-G9a and Flag-GLP, respectively. The FLAG immunoprecipitates were analyzed using anti-FLAG or anti-GFP antibodies. The interaction between FLAG-GLP and GFP-G9a was used as a positive control, and the GLP bands of a and b are the same. (F ) HCT116 cells were separately transfected with pcDNA3.1(+) FLAG-G9a (WT), FLAG-G9a (S211A), or FLAG-G9a (S211D). The FLAG-tagged immunoprecipitates were subjected to Western blotting using an anti-RPA70 antibody. "FLAG" indicates FLAG-tagged G9a WT or its mutants. (G) Bacterially purified GST or GST-RPA70 was coincubated with recombinant G9a (the GST-tag of GST-G9a was cut with human rhinovirus 3C protease). Western blotting was performed to detect G9a protein levels and Coomassie Brilliant Blue (CBB) staining was performed to detect GST or GST-RPA70 levels. The arrow indicates the corresponsive protein bands. (H) Bacterially purified GST-G9a fragments were coincubated with recombinant RPA70 (the GST-tag of GST-RPA70 was cut with HRV3C protease). (Upper) The schematic structure of G9a. ANK repeats: ankyrin repeats domain; E: Glu-rich region; Post: Post-SET domain; Pre: Pre-SET domain; SET: catalytic domain. Western blotting was performed to detect RPA70 protein levels, and CBB staining was performed to detect GST or GSTtagged proteins. The arrows indicate the corresponding protein bands. (I) HCT116 cells were cotransfected with GFP-G9a (WT) and FLAG-RPA70, GFP-G9a (1-350 aa) and FLAG-RPA70, or GFP-G9a (1-630 aa) and FLAG-RPA70. Co-IP was performed to detect the interactions between the GFP-tagged G9a fragments and FLAG-RPA70.
compared with HCT116 G9a-WT cells (Fig. S6D) . Furthermore, Western blot analysis of RPA70 and Rad51 protein levels on chromatin confirmed a moderate decrease in their abundance as a result of G9a deficiency under normal conditions. However, a marked decrease in RPA70 and Rad51 accumulation on chromatin was observed following IR, VP16, or CPT treatment (Fig. 6  C and D and Fig. S6E ). RPA70 recruitment to chromatin upon hydroxyurea (HU) treatment was also impaired by G9a knockout, suggesting that G9a may also have a role in the cellular response to DNA replication stress (Fig. S6F) . Total protein levels of RPA70, RPA32, Rad51, and other DDR proteins were also not affected by G9a deficiency following VP16 treatment (Fig. S6G) . These data suggest that deficiency of G9a in cancer cells impairs RPA and Rad51 foci formation.
To explore the mechanisms by which loading of RPA and Rad51 to DSBs is impaired as a result of G9a deficiency, the ssDNA-binding activity of RPA was investigated in vitro. In the absence of G9a, low levels of RPA could be precipitated with biotin-labeled ssDNA, but this interaction was markedly increased in the presence of functional G9a (Fig. S6I) . G9a deficiency did not affect the binding activity of RPA70 to RPA32 (Fig. S6H) . These results indicate that loss of G9a disturbs the loading of RPA and Rad51 to chromatin in response to DSBs, probably by enhancing the stability of the RPA-ssDNA complex.
We next investigated the downstream events of RPA-ssDNA complex formation. The phosphorylation levels of Chk1 and RPA32, which is activated by RPA-coated ssDNA (43, 44) , were decreased as a result of G9a deficiency (Fig. S7A) . And the percentage of the cells in the G2/M phase decreased ∼10% at 18 h post IR or VP16 withdrawal in G9a-KO cells compared with that in G9a-WT cells (Fig. S7B) . These results indicate that G9a deficiency disturbs the activation of the G2/M DNA damage checkpoint.
Next, the DNA repair efficiency was analyzed in DR-U2OS or EJ-U2OS cells-two well-known cell lines for detecting HR or NHEJ efficiency, respectively (37, 45) . As shown in Fig. 6E , G9a knockdown by siRNA significantly decreased the efficiency of HR (according to GFP expression following I-SceI expression) (P < 0.05), whereas it had little effect on NHEJ. In addition, G9a knockdown did not alter the cell-cycle profiles of DR-U2OS or EJ-U2OS cells (Fig. S7C) . Collectively, G9a has an important role in G2/M checkpoint activation and HR in response to DSBs.
G9a Is Recruited to Chromatin by RPA. RPA-coated ssDNA is a platform for the recruitment of many DNA damage-responsive proteins to chromatin (9); thus we sought to explore whether RPA also recruits G9a to chromatin. As shown in Fig. S8A, RPA70 knockdown impeded the accumulation of G9a on chromatin in response to VP16 treatment. In addition, we monitored the recruitment of G9a to DNA damage stripes in cells depleted in CtIP, an upstream factor of DNA end resection and RPA loading (12) . As shown in Fig. S8 B and C, CtIP depletion markedly impaired GFP-G9a and Cherry-RPA70 recruitment to DNA damage stripes, suggesting that G9a functions downstream of CtIP. Taken together, these results support the idea that G9a is recruited to chromatin by the RPA complex. (C) G9a-WT or G9a-KO HCT116 cells were exposed to IR and recultured under normal conditions for 3 min and 1, 3, and 6 h. Chromatin-bound proteins were subjected to Western blotting with the indicated antibodies. (D) G9a-WT or G9a-KO HCT116 cells were treated with or without VP16 or CPT, and the chromatin-bound proteins were subjected to Western blotting with the indicated antibodies. (E) DR-U2OS or EJ5-U2OS cells were transfected with an siRNA against G9a. Twenty-four hours after transfection, the cells were transfected with I-SceI plasmid. At 48 h after transfection, the cells were harvested and assayed for GFP-positive signals by fluorescence-activated cell sorting (FACS) analysis. The data represent the means ± SD from three independent experiments. Western blotting was performed to detect G9a knockdown efficiency.
Interaction Between G9a and RPA Is Required for DNA Damage Repair.
To confirm the results described above, a rescue experiment was performed whereby G9a (WT) or different G9a mutants were reintroduced into G9a-KO HCT116 cells, and RPA recruitment and cell survival were analyzed. Reintroduction of G9a (WT), G9a (S211D), or G9a (1-630 aa) was sufficient to recruit RPA70 to damaged DNA stripes in G9a-KO cells, but G9a (S211A) failed to rescue RPA70 recruitment (Fig. 7A) , suggesting that both the phosphorylation of G9a at Ser211 and the N terminus of G9a are indispensable for RPA70 recruitment to damaged DNA stripes. We also performed Western blotting in HCT116 G9a-KO cells to confirm this result. As shown in Fig. 7 B and C, overexpression of FLAG-G9a (WT), FLAG-G9a (S211D), or FLAG-G9a (1-630 aa), but not FLAG-G9a (S211A), in G9a-KO cells increased the recruitment of RPA70 and Rad51 to chromatin in response to VP16 treatment. In addition, the decreased efficiency of HR in G9a knockdown cells was rescued in cells in which siRNAresistant G9a (WT) or G9a (S221D) were overexpressed, but not in cells where G9a (S211A) was overexpressed (Fig. 7D) . Consistently, colony formation assay confirmed that the cellsurvival rate increased when G9a (WT) or G9a (S211D) were re-expressed in G9a-KO cells, but not G9a (S211A) (Fig. 7E ). Reexpression of exogenous G9a without the SET catalytic domain [G9a (D960-1210)] failed to increase cell survival in G9a-KO cells (Fig. S9A) , suggesting that G9a methylation activity is required for cell survival under basal conditions. Overall, these data support that the Ser211 phosphorylation of G9a or the N terminus of G9a, which facilitates the interaction between G9a and RPA, is required for DNA damage repair.
Discussion
The present study has identified G9a as a direct and positive regulator of HR. Upon DNA damage, G9a is recruited to chromatin as a result of CK2-mediated phosphorylation. Chromatinenriched G9a can then interact with RPA to permit RPA and Rad51 foci formation. Loss of G9a results in attenuated G2/M checkpoint activation and reduced efficiency of HR. Therefore, a deficiency in G9a will impair cancer-cell survival (Fig. S9B ). G9a is a well-known transcriptional repressor (46) , but also has functions that are independent of its methyltransferase activity. For example, G9a promotes p53-dependent activation of Puma by interacting with histone acetylase p300/CBP (47) , and, in response to glucocorticoid, G9a acts as a platform for the recruitment of gene coactivators (48) . Here, we have identified a role for G9a whereby G9a directly interacts with RPA to help regulate HR in cancer cells.
It is well recognized that modifiers of histone methylation have pivotal roles in the DDR. For example, SETD2 mediates H3K36me3 on DSBs, which recruits LEDGF to chromatin to facilitate DNA end resection (49) . Down-regulation of SUV39H1 The data represent the means ± SD from three independent experiments. (E) HCT116 G9a-KO cells were transfected with G9a (WT), G9a (S211A), or G9a (S211D) and subjected to a colony formation assay. The data represent the means ± SD from three independent experiments. Student's t test (two-tailed): WT versus pcDNA3.1(+) P < 0.05; WT versus S211A, P < 0.05; S211D versus pcDNA3.1(+) P < 0.05; S211D versus S211A, P < 0.05.
methyltransferase activity leads to heterochromatin relaxation and genomic instability in response to DNA damage in cancer cells (50) . In our study, we found that the histone methyltransferase G9a is involved in DNA damage repair. However, we noted a conflicting phenomenon that the reduction of γ-H2AX foci post IR in the cancer cells tested (Fig. S1 F and H) is much faster than what has been previously reported (51, 52) . Although the exact mechanism by which the differing γ-H2AX kinetics occurred in different studies is still unknown, we aimed to examine the kinetics of γ-H2AX post IR in normal human cells. Interestingly, we found that it takes >12 h for the recovery of γ-H2AX signals post IR to basal levels in mouse embryonic fibroblasts (Fig. S1I) , suggesting that the γ-H2AX kinetics may vary depending on the cell line used. Although we could not detect G9a recruitment to IR-induced foci, we found that G9a is readily recruited to DNA damage sites after laser microirradiation. Recent studies have recognized that multiphoton treatment, such as laser microirradiation, causes damage to DNA and proteins (53) (54) (55) . To address whether G9a is involved in DNA damage or protein damage, we observed the recruitment of GFP-G9a to the IR path following laser microirradiation in cells with or without 5-bromo-2′-deoxyuridine (BrdU) treatment. As shown in Fig. S2C , GFP-G9a recruitment to DNA damage sites was significantly enhanced in cells pretreated with BrdU compared with non-BrdU preincubated cells. Considering that BrdU treatment sensitizes cancer cells only to DNA damage but not to protein damage, this result suggests that G9a is implicated in the response to DNA damage and thus recruited to the IR path.
The recruitment of G9a to chromatin is not dependent on the canonical PIKK family members ATM, ATR, and DNA-PK (56) but instead on the kinase CK2. Other substrates of CK2 have already been identified as being important for DNA damage repair. For example, within a few minutes of DNA damage, phosphorylation of HP1-β at Thr51 by CK2 compromises its chromatin-binding activity, leading to HP1-β release from chromatin to facilitate H2AX phosphorylation and initiation of the DDR (57). CK2-mediated phosphorylation of Rad51 at Thr14 triggers its direct binding to NBS1, which promotes Rad51 recruitment to sites of DNA damage and facilitates HR (58) . Thus, compared with the canonical PIKK family substrates, the role of CK2 in mediating substrate phosphorylation is also critical for promoting DNA damage repair.
The repetitive ankyrin domain of G9a is essential for H3K9me1 and H3K9me2 binding (41); however, under most conditions, the recruitment of G9a to chromatin is not dependent on its methylation-binding domain. In nonneuronal cells, the transcriptional repressor NRSF recruits G9a to NRSF target genes (59) . In response to viral infection, the DNA-binding protein PRDI-BF directs G9a to the IFN-β promoter to silence the surrounding chromatin in U2OS osteosarcoma cells (60) . In our study, phosphorylation at Ser211 residue was required for G9a recruitment by RPA to chromatin. In addition, the interaction between G9a and RPA70 was notably impaired in vivo upon mutation of G9a S211 to A211 (Fig. 5F ). However, as demonstrated by in vitro pull-down assay, both recombinant G9a (1-350 aa) and G9a (350-630 aa) portions could bind to RPA70 (Fig. 5H) , suggesting that Ser211 phosphorylation is not required for G9a binding to RPA70 in vitro. This conflicting phenomenon has also been reported in the binding of G9a to CDYL (61) , which suggests that the interaction between G9a and RPA70 may be regulated in vivo by combinatorial posttranslational modifications to both proteins. Therefore, it is possible that G9a Ser211 phosphorylation may lead to the conformational changes of G9a and thus facilitate its binding to RPA70.
RPA is a key eukaryotic ssDNA-binding protein that participates in a variety of DNA biological processes, including DNA replication and DNA repair (9, 62) . Other DNA-binding proteins compete with RPA to bind ssDNA, which is considered to be the main way by which RPA-ssDNA formation is regulated. For example, BRCA2-mediated Rad51-ssDNA nucleoprotein formation dissociates RPA from ssDNA at DSBs to promote DNA strand exchange (63) . Heterogeneous nuclear ribonucleoprotein A1 can also displace RPA from telomeric ssDNA after DNA replication to maintain the length of telomeres (64) . In addition, several proteins regulate the dissociation of RPA from ssDNA by directly binding to RPA70, including SLFN11, which can destabilize the RPA-ssDNA complex (65) . This study found that G9a was directly associated with the N terminus (1-210 aa) of RPA70 and enhanced RPA loading to chromatin, likely by increasing its ssDNA-binding capacity (Fig. S6I) . Mutation of G9a S211 to D211, however, did not markedly change the binding capacity of RPA to ssDNA compared with G9a (S211A) in vitro (Fig. S6J) , suggesting that both G9a WT and G9a mutants could equally enhance RPA affinity to ssDNA in vitro. Considering that the N terminus of RPA70 interacts with numerous proteins (66) , it is also possible that G9a promotes RPA loading to ssDNA by increasing or decreasing the binding ability of other factors to RPA70. The exact mechanism by which G9a promotes RPA foci formation remains to be investigated in further studies.
In the present study, G9a, but not its histone substrate H3K9me2, was found to interact with RPA to facilitate DNA repair via HR. Interestingly, previous studies have suggested that H3K9me2 is required for HR. The levels of H3K9me2 increase at DSBs and H3K9me2-containing H3 peptide has been shown to bind to HA-tagged BRCA1 in vitro (67) . In addition, the interaction between H3K9me2 and HP1 is essential for BRCA1-BARD complex retention at sites of damaged DNA, which can be abolished upon application of the specific G9a inhibitor UNC0638 (40) . Consistently, we also observed increased levels of H3K9me2 at chromatin in response to DNA damage, and this was eliminated by G9a depletion (Fig. S4 D-F) . However, the interaction between H3K9me2 and BRCA1 was not detected in our in vitro peptide pull-down assays (Fig. S5F) . This difference between our study and the previous report (67) may be because the interaction between H3K9me2 and endogenous BRCA1 is weak, causing it to dissociate during the peptide pull-down. As the levels of H3K9me2 were significantly reduced upon G9a knockout in basal conditions, overexpression of the G9a N terminus failed to rescue the cell survival in G9a-KO cells (Fig. S9A) . Taken together, the histone methylation activity of G9a is confirmed to be dispensable for G9a's function in the response to DSBs, but it is indispensable for cancer-cell survival.
In conclusion, this study has identified a regulatory pathway based on a CK2-G9a-RPA axis that is required for RPA foci formation and HR upon DNA damage. This function of G9a in DNA repair provides an aspect by which to understand its role in cancer development and progression and may be exploited in the design of new cancer therapeutics.
Materials and Methods
Laser Microirradiation. Cells grown in culture dishes with a thin glass bottom were transiently transfected with GFP-tagged or m-Cherry-tagged plasmids for 24-36 h and then irradiated with a 365-nm pulsed nitrogen UV laser (16 Hz pulse, 50% laser output) generated using a MicroPoint photo-stimulation system (Andor). This system was directly coupled to the epifluorescence path of a Nikon A1 confocal imaging system, and time-lapse images were captured every 20 s for 10 min.
Chromatin Protein Extraction. Cells were lysed in buffer I (10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.15% Nonidet P-40, 1% protease inhibitor mixture, and 1 mM DTT) for 10 min. After centrifugation at 12,000 × g for 30 s, the cell pellets were washed twice in PBS and then lysed in buffer II (3 mM EDTA, 0.2 mM EGTA, 1% mixture, and 1 mM DTT) for 30 min. After centrifugation at 12,000 × g for 3 min, the supernatant was assumed to contain soluble nucleoproteins (Dt), and the pellets were assumed to contain the chromatin fraction (Chr).
